GC/Chlamydia, HPV lab update

Effective Friday, Dec 11th Main Line Health labs will convert GC/Chlamydia/HPV testing from Roche Cobas instruments to Hologic Panther instruments. The Aptima Combo 2® Assay is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection and differentiation of ribosomal RNA (rRNA) from Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (GC) to aid in the diagnosis of chlamydial and/or gonococcal disease using the Panther® System. These tests will be offered only as combo test, will be build in EPIC as combo test and will require a new collection kits-Aptima kits rather than Roche Cobas kits.

 

The Aptima HPV assay is an in vitro nucleic acid amplification test for the qualitative

detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human

papillomavirus (HPV) in cervical specimens. The high-risk HPV types detected by the assay

include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The Aptima HPV assay

does not discriminate between the 14 high-risk types. Cervical specimens in ThinPrep Pap

Test vials containing PreservCyt Solution and collected with broom-type or cytobrush/spatula

collection devices may be tested with the Aptima HPV assay.

 

If Aptima HPV is positive, Aptima HPV 16 18/45 genotype assay will be performed. Aptima genotype assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) of human papillomavirus (HPV) types 16, 18, and 45 in cervical specimens from women with positive HPV results. The Aptima HPV 16 18/45 genotype assay can differentiate HPV 16 from HPV 18 and/or HPV 45, but does not differentiate between HPV 18 and HPV 45. Cervical specimens in ThinPrep Pap Test vials containing PreservCyt Solution and collected with broom-type or cytobrush/spatula are acceptable specimens.

 

If you have any questions, contact Daniel Lindao at 476-8424 or Dr. Bhagat at 476-3521.

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published.